Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1429.430
- -6.911-0.48%
Weekly Buzz: Tech stocks hit high scores on ominous day
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $4
Agilent Technologies Analyst Ratings
Market Mixed on Friday the 13th | Livestock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Chardan Capital Downgrades Editas Medicine to Neutral
4 Stocks to Watch on Friday: EVGO, ELF and More
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Editas to Cut 65% of Workforce in Strategy Shift; Shelves Lead Gene-editing Program
Stifel Downgrades Editas Medicine to Hold, Lowers Price Target to $3
Thursday Ends in Index Declines | Wall Street Today
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Editas Medicine Analyst Ratings
Market Falls Wednesday, but Googles Chip Impresses | WST
The Analyst Landscape: 6 Takes On Sangamo Therapeutics